Filing Flows › Tonix Pharmaceuticals Holding (TNXP) › Stock forecast & fair value
Tonix Pharmaceuticals Holding (TNXP) stock forecast and price target
Tonix Pharmaceuticals Holding (TNXP) trades at $4.74. 5 analysts' median price target is $26.00 (+449%), from $18.00 to $65.00.
Tonix Pharmaceuticals Holding's latest quarter
Tonix Pharmaceuticals Holding, Q2 2026: revenue $13.5M (+578% year over year), operating margin -314.1%, net loss $40.6M, operating cash flow −$42.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for TNXP stock?
The median of 5 analysts' 12-month targets is $26.00, +449% from $4.74; the range is $18.00 to $65.00. The average rating is strong buy.
Does Tonix Pharmaceuticals Holding usually beat earnings estimates?
It beat the consensus EPS estimate in 25% of the quarters on record.
Is TNXP stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.